KalVista Pharmaceuticals (NASDAQ:KALV) PT Raised to $24.00 at HC Wainwright

KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price target upped by HC Wainwright from $16.00 to $24.00 in a research note issued to investors on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC lifted their price objective on shares of KalVista […]

Leave a Reply

Your email address will not be published.

Previous post KeyCorp Trims Topgolf Callaway Brands (NYSE:MODG) Target Price to $18.00
Next post 5 Patriots offseason fixes: No. 2 — Fortify pass defense